![Post Featured Image](https://www.vantagepartners.com/hubfs/Alliance%20and%20Partnership%20Management2-1.jpg)
Strategic partnerships have long been a major feature of the pharmaceutical industry. In-licensing, out-licensing, joint research, and co-development arrangements between and among biopharmaceutical companies, and with academic research institutions, abound. Approximately 33% of drugs in the pipelines of the top ten pharmaceutical companies were initially developed elsewhere, according to a 2014 WSJ article by Jonathan D. Rockoff. And according to Vantage’s recent alliance benchmarking study, over 80% of bio-pharma respondents report increased alliance activity compared to five years ago.
Our full array of Life Sciences expertise can be viewed here.
Authors:
![Jonathan Hughes headshot](https://www.vantagepartners.com/hubfs/Insights/author_headshots/jonathan_hughes--headshot.jpg)
Jonathan Hughes
![Stuart Price headshot](https://www.vantagepartners.com/hubfs/Insights/author_headshots/Stuart%20Price.jpg)
Stuart Price